Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...

With a unanimous endorsement by an FDA advisory committee and the agency poised to issue an emergency authorization Saturday, the next inflection point for the Johnson & Johnson COVID-19 vaccine will...

Merck & Co. Inc. (NYSE:MRK) no longer expects to supply the U.S. with COVID-19 therapy MK-7110 by June 30 after FDA told the company additional data would be needed to support emergency use authorization. MK-7110,...

NK cell therapy company Artiva Biotherapeutics Inc. raised $120 million in a series B financing led by Venrock Healthcare Capital Partners. Other new investors participating included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton,...

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. to develop therapies for CNS disorders. The universities will receive up to $53 million over 10 years from...

Launched in 2016, Immune-Onc is part of a growing class of immuno-oncology companies converting myeloid cells from immune-suppressing into tumor-suppressing agents. The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed Advisors...

DISEASE CATEGORY: Cancer INDICATION: Melanoma; lung cancer A Yale University and Memorial Sloan Kettering Cancer Center team led by Arvinas Inc. (NASDAQ:ARVN) founder Craig Crews created a PROTAC based on Zelboraf vemurafenib that could treat BRAF...

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...

As Moderna prioritizes maximizing the reach of its COVID-19 vaccine, Thursday’s announcement of the impending departure of longtime CMO Tal Zaks caps a transformational 14 months for the mRNA company and comes during a year when...